Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 7INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 14Prostatic Neoplasms 10Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3HIV Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma, Kaposi 1Recurrence 1Pain 1Myeloid Malignancies 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Lymphoid 1Dendritic Cell Sarcoma, Interdigitating 1Androgen-independent Prostate Cancer 1

Interventions

Rituximab 30ibrutinib 26Bendamustine Hydrochloride 18Cyclophosphamide 17acalabrutinib 14fludarabine 13Lenalidomide 11zanubrutinib 10venetoclax 9Vincristine 7Bortezomib 7pirtobrutinib 5brexucabtagene autoleucel 5Prednisone 5Doxorubicin 5temsirolimus 4parsaclisib 4aflibercept 4Gemcitabine 4ublituximab 3orelabrutinib 3loncastuximab tesirine 3idelalisib 3ibritumomab tiuxetan 3Sensitivity and Specificity 3Antigens, CD19 3tositumomab I-131 2tazemetostat 2pembrolizumab 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Mantle-Cell × Mitoxantrone × Clear all
NCT00656084 2016-11-03

Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell

US Oncology Research

Phase 2 Completed
16 enrolled 9 charts
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡